ctla-4

Anti-Mouse CTLA-4 Antibody is a mouse-derived IgG2b inhibitor targeting CTLA-4 in murine systems.

Ipilimumab (anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.

Tremelimumab is a cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blocking antibody.Tremelimumab is often used in combination with Durvalumab for the treatment of solid cancers such as hepatocellular carcinoma and lung cancer.

Gotistobart (ONC-392) is a humanized anti-CTLA-4 antibody that enhances immunotherapy by selectively depleting regulatory T cells (Treg) within the tumor microenvironment [1].

Davoceticept (ALPN-202; CD80 vIgD-Fc), a monoclonal antibody that targets CTLA-4, is comprised of the (1-107) fragment of CD80 fused to the IGHG1 Fc domain through a peptidyl linker. It is commonly produced in CHO (Chinese Hamster Ovary) cells [1].

Sovipostobart, an immunoglobulin G1-kappa monoclonal antibody targeting CTLA-4 in Homo sapiens, features a cleavable prodomain. This compound serves as both an immunostimulant and antineoplastic [1].

Quavonlimab (MK-1308) is a novel antibody targeting CTLA-4 [1].

Vudalimab, a fully humanized bispecific monoclonal antibody, effectively inhibits both PD-1 and CTLA-4 immune checkpoint receptors. This dual action facilitates the selective activation of T-cells targeting tumors.

Botensilimab (AGEN 1181), a humanized monoclonal antibody targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4), functions as an activator of both innate and adaptive immunity. It is currently being researched for its potential application in cancer treatment [1].

Nurulimab (BCD-145) is a humanized monoclonal antibody targeting cytotoxic T lymphocyte antigen-4 (anti-CTLA-4). It has potential applications in melanoma research [1].

Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody that targets CTLA-4 (CTLA-4), functioning by antagonizing the CTLA-4-signaling-regulated inhibitory checkpoints of immune cell activation.

Bavunalimab (Anti-Human CTLA4xLAG3), a bispecific human monoclonal antibody targeting CTLA-4 and LAG-3, activates T cells in NSG mice and is utilized in cancer research [1].

Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting (DART) antibody that blocks both PD-1 and CTLA-4, enhancing T-cell responses. It is under investigation for the treatment of metastatic castration-resistant prostate cancer (mCRPC) [1] [2] [3].

Tuvonralimab (PSB-205; QL1706), comprising a combination of Iparomlimab and Tuvonralimab [1], functions as a dual immune checkpoint inhibitor through its formulation of anti-PD-1 IgG4 and anti-CTLA-4 IgG1 antibodies.